Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $56.44 USD
Change Today +4.18 / 8.00%
Volume 647.2K
NLNK On Other Exchanges
Symbol
Exchange
Frankfurt
As of 3:59 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

newlink genetics corp (NLNK) Snapshot

Open
$52.80
Previous Close
$52.26
Day High
$56.65
Day Low
$52.54
52 Week High
03/20/15 - $57.47
52 Week Low
10/13/14 - $17.32
Market Cap
1.6B
Average Volume 10 Days
746.3K
EPS TTM
$3.19
Shares Outstanding
28.5M
EX-Date
--
P/E TM
17.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for NEWLINK GENETICS CORP (NLNK)

newlink genetics corp (NLNK) Details

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. Its portfolio includes biologic product candidates based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase pathway and the tryptophan-(2.3)-dioxygenase pathway. The company’s lead product candidate, HyperAcute Pancreas immunotherapy, is being studied in Phase III clinical trials in surgically-resected pancreatic cancer patients, as well as in patients with advanced pancreatic cancer. It is also developing HyperAcute Lung immunotherapy for treating advanced non-small cell lung cancer; and HyperAcute Melanoma immunotherapy for treating advanced melanoma, as well as HyperAcute immunotherapies for renal, prostate, and breast cancers. In addition, the company is developing IDO pathway inhibitors comprising indoximod and NLG919 for metastatic breast cancer and metastatic prostate cancer; NLG2101 for patients with metastatic breast cancer; NLG2102 for treating refractory malignant brain tumors; NLG2103 for patients with advanced melanoma; and NLG2014 for patients with metastatic pancreatic cancer. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

130 Employees
Last Reported Date: 03/16/15
Founded in 1999

newlink genetics corp (NLNK) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $573.2K
President, Chief Operations Officer and Chief...
Total Annual Compensation: $453.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $90.0K
Clinical & Regulatory Compliance Officer and ...
Total Annual Compensation: $312.2K
Vice President of Business Development
Total Annual Compensation: $262.5K
Compensation as of Fiscal Year 2014.

newlink genetics corp (NLNK) Key Developments

Merck and NewLink Genetics Corporation Enter into Licensing and Collaboration Agreement for Investigational Ebola Vaccine

Merck and NewLink Genetics Corporation announced that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLinks investigational rVSV-EBOV (Ebola) vaccine candidate. The vaccine candidate, originally developed by the Public Health Agency of Canada (PHAC), is currently being evaluated in Phase I clinical trials. Pending the results of ongoing Phase I trials the U.S. National Institutes of Health (NIH) has announced plans to initiate, in early 2015, a large randomized, controlled Phase III study to evaluate the safety and efficacy of the rVSVEBOV vaccine and another investigational Ebola vaccine co-developed by the National Institute of Allergy and Infectious Diseases (NIAID) and GlaxoSmithKline. Under the terms of the agreement, Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products. The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics. Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate.

NewLink Genetics Corporation Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

NewLink Genetics Corporation announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of $169,245,000 compared to $294,000 for the same period a year ago. Income from operations was $149,030,000 compared to loss from operations of $7,913,000 for the same period a year ago. Income before taxes was $149,043,000 compared to loss before taxes of $7,916,000 for the same period a year ago. Net income was $126,855,000 compared to net loss of $8,046,000 for the same period a year ago. Net earnings per diluted share were $4.05 compared to net loss per diluted share of $0.31 for the same period a year ago. For the year, the company announced total revenue of $172,592,000 compared to $1,093,000 for the same period a year ago. Income from operations was $117,573,000 compared to loss from operations of $31,141,000 for the same period a year ago. Net income before taxes was $117,633,000 compared to loss before taxes of $31,050,000 for the same period a year ago. Net income was $102,858,000 compared to net loss of $31,180,000 for the same period a year ago. Net earnings per diluted share were $3.32 compared to net loss per diluted share of $1.23 for the same period a year ago.

NewLink Genetics Corporation to Receive $20 Million in Connection with License and Collaboration Agreement with Merck

NewLink Genetics Corporation announced that it had received notification from Merck that the event specified in the license and collaboration agreement between the two companies relating to the further development of the rVSV-EBOV (Ebola) vaccine candidate had been achieved. Under the terms of the agreement, NewLink Genetics will receive a payment of $20 million in connection with the achievement of the event. The event pertains to the initiation of a key clinical trial for the vaccine. The rVSV-EBOV vaccine candidate was originally developed by the Public Health Agency of Canada (PHAC), and licensed by BioProtection Systems Inc. PHAC will be entitled to a payment from NewLink Genetics in connection with this event.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLNK:US $56.44 USD +4.18

NLNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NLNK.
View Industry Companies
 

Industry Analysis

NLNK

Industry Average

Valuation NLNK Industry Range
Price/Earnings 15.8x
Price/Sales 8.5x
Price/Book 7.2x
Price/Cash Flow 14.5x
TEV/Sales 7.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWLINK GENETICS CORP, please visit www.newlinkgenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.